Novel MDM2 Inhibitor XR-2 Exerts Potent Anti-Tumor Efficacy and Overcomes Enzalutamide Resistance in Prostate Cancer.
Wu M, Cui J, Hou H, Li Y, Liu S, Wan L, Zhang L, Huang W, Sun G, Liu J, Jin P, He S, Liu M.
Wu M, et al. Among authors: liu j, liu m, liu s.
Front Pharmacol. 2022 Apr 25;13:871259. doi: 10.3389/fphar.2022.871259. eCollection 2022.
Front Pharmacol. 2022.
PMID: 35548335
Free PMC article.